ClinicalTrials.gg
CompletedNCT04865289LEAP-001Updated Dec 2, 2025Results posted

Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) Versus Chemotherapy for Endometrial Carcinoma (ENGOT-en9 / MK-7902-001) - China Extension Study

A Phase 3 interventional study of Lenvatinib and Pembrolizumab in Endometrial Neoplasms, sponsored by Merck Sharp & Dohme LLC. Completed at 22 sites in China. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-12-02.

Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Registered 1 year 6 months after the study started (first participant enrolled Oct 2019, registered Apr 2021).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
130
Allocation
Randomized
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 15 studies testing lenvatinib in Endometrial Neoplasms — 4 open to participants now, 6 under way, none of them phase 3. lenvatinib · Endometrial Neoplasms.

Enrollment
4th of 15
130 · median 32
Started
2019
with 1 other
Phase 3
3 of 15
none open now
Registered
9th of 15
by date
Lead sponsor
2 of 15
Merck Sharp & Dohme LLC

Among the 15 studies testing lenvatinib in Endometrial Neoplasms, this one is the 4th largest by enrollment, is one of 2 that started in 2019, is one of 3 in phase 3, and was the 9th registered.

Endometrial Neoplasms

1,428 studies on the registry are indexed under Endometrial Neoplasms; 471 are open to participants now.

Browse Endometrial Neoplasms studies →

Open to participants now

4 of the 15 studies testing lenvatinib in Endometrial Neoplasms are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About lenvatinib

lenvatinib: first FDA approval 2015 (LENVIMA), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 357 Endometrial Neoplasms studies recruiting now, 267 (75%) set no upper age limit and 54 (15%) stop at 75 or younger; 26 take children under 18; 23 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 15 studies testing lenvatinib in Endometrial Neoplasms, or all of them as a file.
02

Study summary

The purpose of this study is to compare the efficacy of pembrolizumab + lenvatinib to chemotherapy in female participants with Stage III, IV, or recurrent endometrial carcinoma. It is hypothesized that the combination of pembrolizumab + lenvatinib will be superior to chemotherapy for progression-free survival (PFS) per Response Evaluation Criteria In Solid Tumors version 1.1 (RECIST 1.1) by blinded independent central review (BICR). It is also hypothesized that the combination of pembrolizumab + lenvatinib will be superior to chemotherapy for overall survival (OS).

As of Amendment 7 eligible participants on study completion will be able to transition to an extension study, if available, in which they can continue to receive pembrolizumab monotherapy, lenvatinib monotherapy, or a combination of both pembrolizumab and lenvatinib as received in the parent study.

Read the detailed description

This China extension study will include participants previously enrolled in China in the global study for MK-7902-001 (NCT03884101) plus those enrolled during the China extension enrollment period.

03

Conditions studied

  • Endometrial Neoplasms
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Has Stage III, Stage IV, or recurrent, -confirmed endometrial carcinoma with disease that is either measurable or nonmeasurable but radiographically apparent, per 1.1 as assessed by BICR (note: may have received prior chemotherapy only if administered concurrently with radiation; may have received prior radiation without concurrent chemotherapy; may have received prior hormonal therapy for treatment of endometrial carcinoma, provided that it was discontinued ≥1 week prior to randomization; and may have received 1 prior line of systemic platinum-based and/or neoadjuvant chemotherapy)
  • Has provided sample or newly obtained core or excisional biopsy of a tumor lesion that was not previously irradiated, for determination of mismatch repair (MMR) status
  • Has an (ECOG) performance status of 0 or 1, as assessed within 7 days prior to the first dose of study intervention
  • Is not pregnant or breastfeeding, and is either not a woman of (WOCBP) or is a WOCBP who agrees to use during the study and for ≥120 days after pembrolizumab, ≥30 days after lenvatinib, or ≥180 days after (chemotherapy) [if a WOCBP, a pregnancy test will be required within 24 hours of first dose of study drug]
  • Has adequately controlled blood pressure within 7 days prior to randomization
  • Has adequate organ function based on assessment within 7 days prior to the first dose of study intervention

Exclusion criteria

Exclusion Criteria:

  • Has carcinosarcoma (malignant mixed Műllerian tumor), endometrial leiomyosarcoma or other high grade sarcomas, or endometrial stromal sarcomas
  • Has a central nervous system (CNS) , unless local therapy (e.g., whole brain radiation therapy, surgery, or radiosurgery) has been completed and have discontinued use of for this indication for ≥4 weeks prior to starting study medication (major surgery within 3 weeks of the first dose of study drug will be exclusionary)
  • Has a known additional (other than endometrial carcinoma) that is progressing or has required active treatment in the last 3 years
  • Has gastrointestinal malabsorption or any other condition that might affect the absorption of lenvatinib
  • Has a pre-existing Grade ≥3 gastrointestinal or nongastrointestinal fistula
  • Has radiographic evidence of major blood vessel invasion/infiltration
  • Has active hemoptysis (bright red blood of ≥0.5 teaspoon) within 3 weeks prior to the first dose of study intervention, or tumor bleeding within 2 weeks prior to randomization
  • Has cardiovascular disease within 12 months from first dose of study intervention including Class III or IV congestive heart failure, unstable angina, myocardial infarction, cerebral vascular accident, or cardiac arrhythmia associated with hemodynamic instability
  • Has any infection requiring systemic treatment
  • Has not recovered adequately from any toxicity and/or complications from major surgery prior to randomization
  • Has a known history of (HIV) infection (HIV test is required at screening)
  • Has a known history of (defined as hepatitis B surface antigen [HBsAg] reactive) or known active virus (hepatitis B and C testing is required at screening)
  • Has a history of (noninfectious) pneumonitis that required treatment with steroids, or has current pneumonitis
  • Has a history or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the study, interfere with the participant's participation for the full duration of the study, or is not in the best interest of the participant to participate, in the opinion of the treating investigator
  • Has a known psychiatric or substance abuse disorder that would interfere with cooperation with the requirements of the study
  • Has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy (in dosing exceeding 10 mg daily of prednisone equivalent) or any other form of therapy within 7 days prior to randomization
  • Has an active disease (with the exception of psoriasis) that has required systemic treatment in the past 2 years (i.e., with use of disease modifying agents, corticosteroids or immunosuppressive drugs)
  • Has received prior systemic chemotherapy in any setting for the treatment of endometrial carcinoma (note: prior chemotherapy administered concurrently with radiation is permitted)
  • Has received prior radiotherapy within 4 weeks prior to randomization (participants must have recovered from all radiation-related toxicities, not require corticosteroids, and not have had radiation pneumonitis - a 2-week is permitted for palliative radiation to non-CNS disease and vaginal brachytherapy)
  • Has received prior hormonal therapy for the treatment of endometrial carcinoma within 1 week of randomization
  • Has received prior therapy with any treatment targeting vascular endothelial growth factor (VEGF)-directed angiogenesis, an anti-programmed cell death (PD)-1, anti-PD ligand (L)1, or anti-PD L2 agent, or with an agent directed to another stimulatory or co-inhibitory T-cell receptor (e.g., , OX 40, CD137)
  • Has received a live or within 30 days prior to the first dose of study intervention
  • Has known intolerance to study intervention (or any of the )
  • Has had an allogenic tissue/solid organ transplant
  • Is currently participating in or has participated in a study of an agent or has used an investigational device within 4 weeks prior to randomization
Terms in these criteria, in plain language(22)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
130 participants (actual)

Study arms

  • Experimental
    Lenvatinib + Pembrolizumab

    Participants receive lenvatinib daily and pembrolizumab once at the start of each 3-week treatment cycle.

    Drug: Lenvatinib · Biological: Pembrolizumab

  • Active comparator
    Paclitaxel + Carboplatin

    Participants receive paclitaxel and carboplatin once at the start of each 3-week treatment cycle.

    Drug: Paclitaxel · Drug: Carboplatin

Interventions

  • Lenvatinib 4 mg or 10 mg capsules at a total daily dose of 20 mg taken by mouth once per day.

    Also known as: E7080, MK-7902, LENVIMA®

  • BiologicalPembrolizumab

    Pembrolizumab 200 mg IV infusion given on Day 1 of each cycle.

    Also known as: MK-3475, KEYTRUDA®

  • Paclitaxel 175 mg/m\^2 IV infusion given on Day 1 of each cycle.

    Also known as: TAXOL®, ONXAL®

  • Carboplatin 10 mg/mL IV infusion at a total dose of are-under-the-curve (AUC) 6 (per Calvert's formula) given on Day 1 of each cycle.

    Also known as: PARAPLATIN®

06

What researchers measure

Primary outcomes

  1. Progression-free Survival (PFS) Based on Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as Assessed by Blinded Independent Central Review (BICR) in Mismatch Repair Proficient (pMMR) Participants

    PFS was defined as the time from randomization to the first documented progressive disease (PD) per RECIST 1.1 based on BICR, or death due to any cause, whichever occurred first. Per RECIST 1.1, PD was defined as ≥20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum had to demonstrate an absolute increase of ≥5 mm. The appearance of one or more new lesions was also considered PD. The PFS of pMMR participants was presented.

    Time frame: Up to approximately 45 months

  2. PFS Based on RECIST 1.1 as Assessed by BICR in All Randomized Participants

    PFS was defined as the time from randomization to the first documented PD per RECIST 1.1 based on BICR, or death due to any cause, whichever occurred first. Per RECIST 1.1, PD was defined as ≥20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum had to demonstrate an absolute increase of ≥5 mm. The appearance of one or more new lesions was also considered PD. The PFS of all randomized participants was presented.

    Time frame: Up to approximately 45 months

  3. Overall Survival (OS) in pMMR Participants

    OS was measured from the time of randomization up to death due to any cause. Participants without documented death at the time of the final analysis were to be censored at the date of the last follow-up. The OS for pMMR participants is presented.

    Time frame: Up to approximately 45 months

  4. OS in All Randomized Participants

    OS was measured from the time of randomization up to death due to any cause. Participants without documented death at the time of the final analysis were to be censored at the date of the last follow-up. The OS for all randomized participants is presented.

    Time frame: Up to approximately 45 months

Secondary outcomes

  1. Objective Response Rate (ORR) Based on RECIST 1.1 as Assessed by BICR in pMMR Participants

    ORR was defined as the percentage of participants who had a Complete Response (CR: Disappearance of all target lesions) or a Partial Response (PR: At least a 30% decrease in the sum of diameters of target lesions) as assessed using RECIST 1.1. The percentage of pMMR participants who experienced a CR or PR is presented.

    Time frame: Up to approximately 45 months

  2. ORR Based on RECIST 1.1 as Assessed by BICR in All Randomized Participants

    ORR was defined as the percentage of participants who had a CR: Disappearance of all target lesions or a PR: At least a 30% decrease in the sum of diameters of target lesions as assessed using RECIST 1.1. The percentage of all randomized participants who experienced a CR or PR is presented.

    Time frame: Up to approximately 45 months

  3. Mean Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire Core-30 (QLQ-C30) Global Health Status/Quality of Life (Items 29 and 30) Score in pMMR Participants

    The EORTC QLQ-C30 was developed to assess the quality of life of patients with cancer. Participant responses to the questions "How would you rate your overall health during the past week?" and "How would you rate your overall quality of life during the past week?" were scored on a 7-point scale (1=Very Poor to 7=Excellent). The combined score of Global Health Status (EORTC QLQ-C30 Item 29) and Quality of Life (EORTC QLQ-C30 Item 30) was computed by averaging the raw scores of the 2 items and then applying a linear transformation to standardize the average score, so that the combined scores ranged from 0-100. A higher score indicates a better outcome. The change from baseline in GHS/QoL combined score was reported for each arm.

    Time frame: Baseline and up to approximately 18 weeks

  4. Mean Change From Baseline in EORTC QLQ-C30 Global Health Status/Quality of Life (Items 29 and 30) Score in All Randomized Participants

    The EORTC QLQ-C30 was developed to assess the quality of life of patients with cancer. Participant responses to the questions "How would you rate your overall health during the past week?" and "How would you rate your overall quality of life during the past week?" were scored on a 7-point scale (1=Very Poor to 7=Excellent). The combined score of Global Health Status (EORTC QLQ-C30 Item 29) and Quality of Life (EORTC QLQ-C30 Item 30) was computed by averaging the raw scores of the 2 items and then applying a linear transformation to standardize the average score, so that the combined scores ranged from 0-100. A higher score indicates a better outcome. The change from baseline in GHS/QoL combined score was reported for each arm.

    Time frame: Baseline and up to approximately 18 weeks

  5. Number of Participants Experiencing an Adverse Event (AE)

    An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention.

    Time frame: From first dose date to 120 days after last dose date (up to approximately 58 months)

  6. Number of Participants Experiencing a Serious Adverse Event (SAE)

    An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An SAE is an AE that results in death, is life-threatening, requires or prolongs hospitalization, results in persistent or significant disability, is a congenital birth defect, or is another important medical event.

    Time frame: From first dose date to 120 days after last dose date (up to approximately 58 months)

  7. Number of Participants Experiencing an Immune-related AE (irAE)

    An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Immune-related AEs (irAEs) were AEs that were considered immune-mediated or potentially immune-mediated and are well-documented for pembrolizumab. These irAEs may occur shortly after the first dose or several months after the last dose of pembrolizumab treatment and may affect more than one body system simultaneously. The number of participants with irAEs was reported for each arm.

    Time frame: From first dose date to 120 days after last dose date (up to approximately 58 months)

  8. Number of Participants Discontinuing From Study Treatment Due to an AE(s)

    An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The number of participants who discontinued study treatment due to an AE was reported for each arm.

    Time frame: From first dose date to last dose date (up to approximately 54 months)

07

Results

Posted Oct 18, 2024

Participant flow

130 participants were enrolled in China. 66 participants were randomized in the global portion for MK-7902-001 (NCT03884101) and 64 in the China extension portion.

Participant flow — Overall Study
MilestoneLenvatinib + PembrolizumabPaclitaxel + Carboplatin
Started7456
Treated7356
Completed00
Not completed7456
Withdrew: Death3425
Withdrew: Physician decision2727
Withdrew: Sponsor decision111
Withdrew: Withdrawal by subject23

Outcome measures

PrimaryProgression-free Survival (PFS) Based on Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as Assessed by Blinded Independent Central Review (BICR) in Mismatch Repair Proficient (pMMR) Participants

PFS was defined as the time from randomization to the first documented progressive disease (PD) per RECIST 1.1 based on BICR, or death due to any cause, whichever occurred first. Per RECIST 1.1, PD was defined as ≥20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum had to demonstrate an absolute increase of ≥5 mm. The appearance of one or more new lesions was also considered PD. The PFS of pMMR participants was presented.

Time frame:
Up to approximately 45 months
Reported as:
Median · Months
Progression-free Survival (PFS) Based on Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as Assessed by Blinded Independent Central Review (BICR) in Mismatch Repair Proficient (pMMR) Participants
MonthsLenvatinib + PembrolizumabPaclitaxel + Carboplatin
Progression-free Survival (PFS) Based on Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as Assessed by Blinded Independent Central Review (BICR) in Mismatch Repair Proficient (pMMR) Participants10.3 (6.4 to 12.7)10.2 (8.3 to 10.6)
Statistical analysis
  • Lenvatinib + Pembrolizumab vs Paclitaxel + Carboplatin · Hazard ratio (hr): 0.85 · 95% CI 0.51 to 1.41
PrimaryPFS Based on RECIST 1.1 as Assessed by BICR in All Randomized Participants

PFS was defined as the time from randomization to the first documented PD per RECIST 1.1 based on BICR, or death due to any cause, whichever occurred first. Per RECIST 1.1, PD was defined as ≥20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum had to demonstrate an absolute increase of ≥5 mm. The appearance of one or more new lesions was also considered PD. The PFS of all randomized participants was presented.

Time frame:
Up to approximately 45 months
Reported as:
Median · Months
PFS Based on RECIST 1.1 as Assessed by BICR in All Randomized Participants
MonthsLenvatinib + PembrolizumabPaclitaxel + Carboplatin
PFS Based on RECIST 1.1 as Assessed by BICR in All Randomized Participants11.7 (8.3 to 19.4)10.3 (8.3 to 12.5)
Statistical analysis
  • Lenvatinib + Pembrolizumab vs Paclitaxel + Carboplatin · Hazard ratio (hr): 0.76 · 95% CI 0.48 to 1.21
PrimaryOverall Survival (OS) in pMMR Participants

OS was measured from the time of randomization up to death due to any cause. Participants without documented death at the time of the final analysis were to be censored at the date of the last follow-up. The OS for pMMR participants is presented.

Time frame:
Up to approximately 45 months
Reported as:
Median · Months
Overall Survival (OS) in pMMR Participants
MonthsLenvatinib + PembrolizumabPaclitaxel + Carboplatin
Overall Survival (OS) in pMMR Participants37.1 (19.5 to NA)NA (21.7 to NA)
Statistical analysis
  • Lenvatinib + Pembrolizumab vs Paclitaxel + Carboplatin · Log Rank · p = 0.5831415 · Hazard ratio (hr): 1.17 · 95% CI 0.64 to 2.15Based on Cox regression model with Efron's method for tie handling with treatment as a covariate.
  • Lenvatinib + Pembrolizumab vs Paclitaxel + Carboplatin · Log Rank · p = 0.6980186 · Hazard ratio (hr): 1.17 · 95% CI 0.64 to 2.15Based on Cox regression model with Efron's method for tie handling with treatment as a covariate.
PrimaryOS in All Randomized Participants

OS was measured from the time of randomization up to death due to any cause. Participants without documented death at the time of the final analysis were to be censored at the date of the last follow-up. The OS for all randomized participants is presented.

Time frame:
Up to approximately 45 months
Reported as:
Median · Months
OS in All Randomized Participants
MonthsLenvatinib + PembrolizumabPaclitaxel + Carboplatin
OS in All Randomized ParticipantsNA (29.8 to NA)NA (25.1 to NA)
Statistical analysis
  • Lenvatinib + Pembrolizumab vs Paclitaxel + Carboplatin · Log Rank · p = 0.52046 · Hazard ratio (hr): 1.01 · 95% CI 0.57 to 1.80Based on Cox regression model with Efron's method for tie handling with treatment as a covariate.
SecondaryObjective Response Rate (ORR) Based on RECIST 1.1 as Assessed by BICR in pMMR Participants

ORR was defined as the percentage of participants who had a Complete Response (CR: Disappearance of all target lesions) or a Partial Response (PR: At least a 30% decrease in the sum of diameters of target lesions) as assessed using RECIST 1.1. The percentage of pMMR participants who experienced a CR or PR is presented.

Time frame:
Up to approximately 45 months
Reported as:
Number · Percentage of Participants
Objective Response Rate (ORR) Based on RECIST 1.1 as Assessed by BICR in pMMR Participants
Percentage of ParticipantsLenvatinib + PembrolizumabPaclitaxel + Carboplatin
Objective Response Rate (ORR) Based on RECIST 1.1 as Assessed by BICR in pMMR Participants50.9 (37.1 to 64.6)61.4 (45.5 to 75.6)
Statistical analysis
  • Lenvatinib + Pembrolizumab vs Paclitaxel + Carboplatin · Miettinen & Nurminen · p = 0.8497 · Difference in percentage: -10.5 · 95% CI -29.2 to 9.3One sided p value for testing. H0: difference in % = 0 versus H1: difference in % \> 0.
SecondaryORR Based on RECIST 1.1 as Assessed by BICR in All Randomized Participants

ORR was defined as the percentage of participants who had a CR: Disappearance of all target lesions or a PR: At least a 30% decrease in the sum of diameters of target lesions as assessed using RECIST 1.1. The percentage of all randomized participants who experienced a CR or PR is presented.

Time frame:
Up to approximately 45 months
Reported as:
Number · Percentage of Participants
ORR Based on RECIST 1.1 as Assessed by BICR in All Randomized Participants
Percentage of ParticipantsLenvatinib + PembrolizumabPaclitaxel + Carboplatin
ORR Based on RECIST 1.1 as Assessed by BICR in All Randomized Participants56.9 (44.7 to 68.6)66.1 (52.2 to 78.2)
Statistical analysis
  • Lenvatinib + Pembrolizumab vs Paclitaxel + Carboplatin · Miettinen & Nurminen · p = 0.8522 · Difference in percentage: -9.1 · 95% CI -25.5 to 8.0One sided p value for testing. H0: difference in % = 0 versus H1: difference in % \> 0.
SecondaryMean Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire Core-30 (QLQ-C30) Global Health Status/Quality of Life (Items 29 and 30) Score in pMMR Participants

The EORTC QLQ-C30 was developed to assess the quality of life of patients with cancer. Participant responses to the questions "How would you rate your overall health during the past week?" and "How would you rate your overall quality of life during the past week?" were scored on a 7-point scale (1=Very Poor to 7=Excellent). The combined score of Global Health Status (EORTC QLQ-C30 Item 29) and Quality of Life (EORTC QLQ-C30 Item 30) was computed by averaging the raw scores of the 2 items and then applying a linear transformation to standardize the average score, so that the combined scores ranged from 0-100. A higher score indicates a better outcome. The change from baseline in GHS/QoL combined score was reported for each arm.

Time frame:
Baseline and up to approximately 18 weeks
Reported as:
Least squares mean · Scores on a scale
Mean Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire Core-30 (QLQ-C30) Global Health Status/Quality of Life (Items 29 and 30) Score in pMMR Participants
Scores on a scaleLenvatinib + PembrolizumabPaclitaxel + Carboplatin
Mean Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire Core-30 (QLQ-C30) Global Health Status/Quality of Life (Items 29 and 30) Score in pMMR Participants-7.00 (-12.49 to -1.51)-4.87 (-11.52 to 1.79)
Statistical analysis
  • Lenvatinib + Pembrolizumab vs Paclitaxel + Carboplatin · cLDA model · p = 0.6138 · Difference in least square means: -2.14 · 95% CI -10.54 to 6.27
SecondaryMean Change From Baseline in EORTC QLQ-C30 Global Health Status/Quality of Life (Items 29 and 30) Score in All Randomized Participants

The EORTC QLQ-C30 was developed to assess the quality of life of patients with cancer. Participant responses to the questions "How would you rate your overall health during the past week?" and "How would you rate your overall quality of life during the past week?" were scored on a 7-point scale (1=Very Poor to 7=Excellent). The combined score of Global Health Status (EORTC QLQ-C30 Item 29) and Quality of Life (EORTC QLQ-C30 Item 30) was computed by averaging the raw scores of the 2 items and then applying a linear transformation to standardize the average score, so that the combined scores ranged from 0-100. A higher score indicates a better outcome. The change from baseline in GHS/QoL combined score was reported for each arm.

Time frame:
Baseline and up to approximately 18 weeks
Reported as:
Least squares mean · Scores on a scale
Mean Change From Baseline in EORTC QLQ-C30 Global Health Status/Quality of Life (Items 29 and 30) Score in All Randomized Participants
Scores on a scaleLenvatinib + PembrolizumabPaclitaxel + Carboplatin
Mean Change From Baseline in EORTC QLQ-C30 Global Health Status/Quality of Life (Items 29 and 30) Score in All Randomized Participants-6.69 (-11.42 to -1.96)-5.96 (-11.65 to -0.26)
Statistical analysis
  • Lenvatinib + Pembrolizumab vs Paclitaxel + Carboplatin · cLDA model · p = 0.8398 · Difference in least square means: -0.73 · 95% CI -7.93 to 6.46
SecondaryNumber of Participants Experiencing an Adverse Event (AE)

An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention.

Time frame:
From first dose date to 120 days after last dose date (up to approximately 58 months)
Reported as:
Count of participants · Participants
Number of Participants Experiencing an Adverse Event (AE)
ParticipantsLenvatinib + PembrolizumabPaclitaxel + Carboplatin
Number of Participants Experiencing an Adverse Event (AE)7256
SecondaryNumber of Participants Experiencing a Serious Adverse Event (SAE)

An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An SAE is an AE that results in death, is life-threatening, requires or prolongs hospitalization, results in persistent or significant disability, is a congenital birth defect, or is another important medical event.

Time frame:
From first dose date to 120 days after last dose date (up to approximately 58 months)
Reported as:
Count of participants · Participants
Number of Participants Experiencing a Serious Adverse Event (SAE)
ParticipantsLenvatinib + PembrolizumabPaclitaxel + Carboplatin
Number of Participants Experiencing a Serious Adverse Event (SAE)4017
SecondaryNumber of Participants Experiencing an Immune-related AE (irAE)

An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Immune-related AEs (irAEs) were AEs that were considered immune-mediated or potentially immune-mediated and are well-documented for pembrolizumab. These irAEs may occur shortly after the first dose or several months after the last dose of pembrolizumab treatment and may affect more than one body system simultaneously. The number of participants with irAEs was reported for each arm.

Time frame:
From first dose date to 120 days after last dose date (up to approximately 58 months)
Reported as:
Count of participants · Participants
Number of Participants Experiencing an Immune-related AE (irAE)
ParticipantsLenvatinib + PembrolizumabPaclitaxel + Carboplatin
Number of Participants Experiencing an Immune-related AE (irAE)4910
SecondaryNumber of Participants Discontinuing From Study Treatment Due to an AE(s)

An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The number of participants who discontinued study treatment due to an AE was reported for each arm.

Time frame:
From first dose date to last dose date (up to approximately 54 months)
Reported as:
Count of participants · Participants
Number of Participants Discontinuing From Study Treatment Due to an AE(s)
ParticipantsLenvatinib + PembrolizumabPaclitaxel + Carboplatin
Number of Participants Discontinuing From Study Treatment Due to an AE(s)328

Adverse events

Collected over From randomization to the date of death or last participant data collection (up to approximately 61 months).. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Lenvatinib + Pembrolizumab34/74 (45.9%)40/73 (54.8%)72/73 (98.6%)
Paclitaxel + Carboplatin25/56 (44.6%)17/56 (30.4%)55/56 (98.2%)
Most frequent serious events
Showing 10 of 74
Most frequent serious events
EventLenvatinib + PembrolizumabPaclitaxel + Carboplatin
AnaemiaBlood and lymphatic system disorders0/735/56
Platelet count decreasedInvestigations1/733/56
GranulocytopeniaBlood and lymphatic system disorders0/732/56
MyelosuppressionBlood and lymphatic system disorders2/731/56
Arteriosclerosis coronary arteryCardiac disorders2/730/56
AscitesGastrointestinal disorders2/731/56
PainGeneral disorders2/730/56
CholecystitisHepatobiliary disorders2/730/56
Hepatic function abnormalHepatobiliary disorders2/730/56
PneumoniaInfections and infestations2/730/56
Most frequent other events
Showing 10 of 88
Most frequent other events
EventLenvatinib + PembrolizumabPaclitaxel + Carboplatin
AlopeciaSkin and subcutaneous tissue disorders6/7345/56
AnaemiaBlood and lymphatic system disorders21/7343/56
White blood cell count decreasedInvestigations19/7337/56
ProteinuriaRenal and urinary disorders48/735/56
HypertensionVascular disorders47/733/56
Neutrophil count decreasedInvestigations17/7336/56
HypothyroidismEndocrine disorders44/733/56
Platelet count decreasedInvestigations28/7328/56
HypoaesthesiaNervous system disorders2/7326/56
Aspartate aminotransferase increasedInvestigations33/7313/56

Baseline characteristics

All Chinese participants who were randomized to the global study (NCT03884101) and to the extension portion.

Age, Continuous
Age, Continuous(Years)Lenvatinib + PembrolizumabPaclitaxel + CarboplatinTotal
Mean61.5 ± 8.158.3 ± 7.360.1 ± 7.9
Sex: Female, Male
Sex: Female, Male(Participants)Lenvatinib + PembrolizumabPaclitaxel + CarboplatinTotal
Female7456130
Male000
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Lenvatinib + PembrolizumabPaclitaxel + CarboplatinTotal
Hispanic or Latino000
Not Hispanic or Latino7455129
Unknown or Not Reported011
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Lenvatinib + PembrolizumabPaclitaxel + CarboplatinTotal
American Indian or Alaska Native000
Asian7456130
Native Hawaiian or Other Pacific Islander000
Black or African American000
White000
More than one race000
Unknown or Not Reported000
Eastern Cooperative Oncology Group (ECOG) Performance Status
Eastern Cooperative Oncology Group (ECOG) Performance Status(Participants)Lenvatinib + PembrolizumabPaclitaxel + CarboplatinTotal
ECOG = 0352964
ECOG = 1392766
Prior Chemotherapy and/or Chemoradiation
Prior Chemotherapy and/or Chemoradiation(Participants)Lenvatinib + PembrolizumabPaclitaxel + CarboplatinTotal
Yes211839
No533891
Mismatch Repair (MMR) Status
Mismatch Repair (MMR) Status(Participants)Lenvatinib + PembrolizumabPaclitaxel + CarboplatinTotal
dMMR171229
pMMR5744101
08

Study locations

22 sites
  • Anhui Cancer Hospital-Gynecological Oncology ( Site 2509)
    Hefei, Anhui 230031, China
  • Beijing Obstetrics and Gynecology Hospital Capital Medical University ( Site 2505)
    Beijing, Beijing Municipality 100032, China
  • Peking Union Medical College Hospital ( Site 2501)
    Beijing, Beijing Municipality 100032, China
  • Beijing Cancer Hospital ( Site 2504)
    Beijing, Beijing Municipality 100142, China
  • Chongqing Cancer Hospital ( Site 2513)
    Chongqing, Chongqing Municipality 400030, China
  • The First Affiliated hospital of Xiamen University-Obstetrics and gynecology department ( Site 2522)
    Xiamen, Fujian 361003, China
  • The First Affiliated Hospital.Sun Yat-sen University ( Site 2507)
    Guangzhou, Guangdong 510080, China
  • Guang Xi Tumour Hospital, Department of Chemotherapy ( Site 2517)
    Nanning, Guangxi 530021, China
  • Harbin Medical University Cancer Hospital ( Site 2520)
    Harbin, Heilongjiang 150081, China
  • Hubei Cancer Hospital ( Site 2510)
    Wuhan, Hubei 430079, China
  • Xiangya Hospital Central-South University ( Site 2512)
    Changsha, Hunan 410008, China
  • Hunan Cancer Hospital ( Site 2523)
    Changsha, Hunan 410013, China
  • Nanjing Maternity and Child Health Care Hospital ( Site 2508)
    Nanjing, Jiangsu 210011, China
  • Jiangxi Maternal and Child Health Hospital ( Site 2519)
    Nanchang, Jiangxi 530021, China
  • The First Hospital Of Jilin University ( Site 2518)
    Changchun, Jilin 130012, China
  • The first affiliated Hospital of Xi an Jiaotong University ( Site 2502)
    Xi'an, Shaanxi 710061, China
  • Fudan University Shanghai Cancer Center ( Site 2500)
    Shanghai, Shanghai Municipality 200032, China
  • Obstetrics and Gynecology Hosp. Fudan University ( Site 2503)
    Shanghai, Shanghai Municipality 200090, China
  • Shanghai First Maternity and Infant Hospital ( Site 2524)
    Shanghai, Shanghai Municipality 201204, China
  • The First Affiliated Hospital of Xinjiang Medical University ( Site 2515)
    Ürümqi, Xinjiang 830054, China
  • Women s Hospital School of Medicine Zhejiang University ( Site 2511)
    Hangzhou, Zhejiang 310006, China
  • Zhejiang Cancer Hospital ( Site 2506)
    Hangzhou, Zhejiang 310022, China
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf

Data sharing details ↗ · engagezone.msd.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2019 to primary completion in Oct 2023, 47 months.

Results were first posted in Oct 2024, 1 year after primary completion.

Of 44 phase 3 interventional studies under Endometrial Neoplasms, half reached primary completion within 53 months of starting (the median), counting those still running; a quarter within 45 and three quarters within 126. This study's 47 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 26, 2021
First posted
Apr 29, 2021
StartActual
Oct 22, 2019
Primary completionActual
Oct 2, 2023
CompletionActual
Jan 14, 2025
Results first posted
Oct 18, 2024
Last update
Dec 2, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 2, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04865289
Collaborators
Eisai Inc.
Responsible party
Sponsor
First posted
Apr 29, 2021
Start date
Oct 22, 2019
Primary completion
Oct 2, 2023
Completion
Jan 14, 2025
Results posted
Oct 18, 2024
Last update
Dec 2, 2025

Study contacts

Medical Director
study director · Merck Sharp & Dohme LLC

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Lenvatinib · Pembrolizumab

Start the discussion